Tarsus Pharmaceuticals (TARS) Payables (2023 - 2026)

Tarsus Pharmaceuticals (TARS) posted quarterly Payables of $24.1 million for Q1 2026, up 47.26% quarter-over-quarter from $16.4 million in Q4 2025.

Tarsus Pharmaceuticals (TARS) Payables (2023 - 2026) Analysis & Trends

Tarsus Pharmaceuticals' Payables history runs 4 years deep, the most recent figure standing at $24.1 million for Q1 2026.

In Q1 2026, Payables changed N/A year-over-year to $24.1 million; the TTM figure through Mar 2026 stood at $24.1 million (changed N/A YoY), while the FY2025 annual figure was $16.4 million, up 73.98% from the prior year.
Payables for Q1 2026 stood at $24.1 million, up from $16.4 million in the prior quarter.
The five-year high for Payables was $24.1 million in Q1 2026, with the low at $400000.0 in Q1 2023.
The 4-year median for Payables is $12.9 million (2024), against an average of $12.6 million.
Peak annual rise in Payables reached 73.98% in 2025, while the deepest fall reached 73.98% in 2025.
Tarsus Pharmaceuticals' Payables stood at $400000.0 in 2023, then jumped by 2254.75% to $9.4 million in 2024, then soared by 73.98% to $16.4 million in 2025, then surged by 47.26% to $24.1 million in 2026.
Business Quant data shows TARS's Payables at $24.1 million in Q1 2026, $16.4 million in Q4 2025, and $9.4 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Payables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	429.50 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.16 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.52 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	88.42 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	470.30 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	3.05 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	35.57 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	108.02 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	428.93 Mn
10	Tarsus Pharmaceuticals	2.99 Bn	2.54 Bn	161.80 Mn	40.14 Mn

Download Data